Facilitate growth
Decentralized Clinical Trials: What’s the Vendor Landscape?
Everest Group brings clarity to the decentralized clinical trials vendor landscape
Decentralized Clinical Trials, or DCTs, are clinical trials in which data is collected through sensors or remote monitoring devices carried by a patient without the need to visit a site. They can deliver many benefits to pharmaceutical companies, including cost savings, better patient recruitment and retention, and improved data quality.
Before the COVID-19 pandemic, while there was significant information on DCT benefits, there were only a few pilots. However, recently decentralized clinical trials have proved to be a saving grace to restart paused clinical trials. Additionally, recent technological advances, the proliferation of wearables, and the FDA’s push for the industry to adopt DCTs following the COVID-19 situation have made the DCT landscape ripe for disruption.
But with things moving so quickly, how do pharmaceutical companies choose a DCT provider?
In our Decentralized Clinical Trial Products PEAK Matrix® Assessment 2021, we explore this quickly developing market and assess the capabilities of 15 IT vendors specific to DCT products. The assessment thoroughly details the vendors' capabilities, potential, and market impact.
Learn more about the emerging decentralized clinical trial landscape through key findings from the assessment and our other research on this topic.
How Decentralized Clinical Trials Put the Patient Experience at the Forefront
What factors are enterprise buyers looking for Decentralized Clinical Trial (DCT) vendors to provide in their platforms to increase satisfaction and ultimately drive patient enrollments? When COVID-19 brought traditional clinical trials to an abrupt halt, decentralized clinical trials proved to be a solution for sponsors looking to safely restart their paused research activities. The top reason for moving to this model has been its patient-centered focus, making it easier for more people from a broader geographic area to participate in trials without needing to visit a site.
The growing mainstream acceptance for decentralized clinical trials has increased the appetite among clinical research organizations (CROs) and sponsors to adopt the latest technologies and virtual models for clinical trials. This has resulted in an uptick in innovation and decentralized clinical trial product adoption. We see decentralized clinical trial vendors increasingly focus on co-innovation, continuous product improvement, and market education to help clients get started on their DCT journey.
The most promising benefit is the opportunity to enhance the patient experience – a benefit that two out of three decentralized clinical trial product buyers also agree with based on Everest Group interviews. Other advantages of decentralized clinical trials include reducing trial costs and timelines, attracting a more diverse patient population, and capturing real-time data for trials. With decentralized clinical trials, patients can now take part in a study from the comfort of their homes, spend more time with their family members, and focus on work and other responsibilities. This mode of clinical trial also opens the door to patients who have mobility issues and allows sponsors to reach a global audience, increasing inclusivity and diversion.
This new patient-centric approach is driving increased enrollment and retention rates. With these valuable benefits, it is not surprising that having a people-orientated platform has become central to enterprise buyers in making their sourcing decisions – even more so than innovation or reviews from other buyers.
Virtual Trials Series
Part 1 of 5: Decentralized Clinical Trial Products #PEAKMatrix® Assessment 2021 | #VirtualTrials
3:18Part 3 of 5: Decentralized Clinical Trial (DCT) Products #PEAKMatrix® Assessment 2021 #VirtualTrials
3:54Clinical Trial Vendors
To solve for better vendor selection and management in clinical trials, it is important to remember to weigh clinical trial vendors on several capability and market success-related dimensions.
Current Challenges in Clinical Trial Patient Recruitment and Enrollment
Though the solution to the current challenges in clinical trial patient recruitment and enrollment is technology and connected systems, the focus should be on improving the patient experience and building the future towards a patient-intuitive smart decentralized clinical trial solution suite.
Clinical Trial Solutions
Decentralized Clinical Trials (DCT) provide a multitude of clinical trial solutions post-pandemic. With the COVID-19 pandemic accelerating the adoption of decentralized clinical trials, it has put the patient’s experience at the forefront of importance.
